Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

IMPORTANCE: Only 1 randomized clinical trial has shown the superiority of immune checkpoint inhibitors in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) in the first-line setting. OBJECTIVES: To determine whether avelumab (an...

Descripción completa

Detalles Bibliográficos
Autores principales: Taïeb, Julien, Bouche, Olivier, André, Thierry, Le Malicot, Karine, Laurent-Puig, Pierre, Bez, Jérémie, Toullec, Clémence, Borg, Christophe, Randrian, Violaine, Evesque, Ludovic, Corbinais, Stéphane, Perrier, Hervé, Buecher, Bruno, Di Fiore, Frederic, Gallois, Claire, Emile, Jean Francois, Lepage, Côme, Elhajbi, Farid, Tougeron, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401392/
https://www.ncbi.nlm.nih.gov/pubmed/37535388
http://dx.doi.org/10.1001/jamaoncol.2023.2761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401392/
https://www.ncbi.nlm.nih.gov/pubmed/37535388
http://dx.doi.org/10.1001/jamaoncol.2023.2761

Ejemplares similares